July 27, 2021

Biocomposites receives Canadian approval for Stimulan – Med-Tech Innovation

Biocomposites, a medical devices company that engineers, manufactures and markets products for use in infection management in bone and soft tissue, has announced that its Stimulan products have gained a new Canadian approval for mixing with antibiotics: vancomycin, gentamicin and tobramycin, for use in treating bacterial infection in soft tissue surrounding bone.

The Stimulan Rapid Cure and Stimulan Kit products are the first and only approved calcium matrices that can carry an antibiotic to treat bacterial infection. This offers surgeons the flexibility to apply a broad spectrum of ‘off-the-shelf’ antibiotics at concentrations that will support their patient-specific treatment plans. Stimulan targets high concentrations of antibiotic at the point of infection at levels unachievable systemically – which lowers rates of reinfection, saves costs and improves…

Read full article here: www.med-technews.com